ArticleCancers2024

Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor.

Ian M McElree et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.